Compare IGIC & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | SGP |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 968.0M |
| IPO Year | 2019 | 2026 |
| Metric | IGIC | SGP |
|---|---|---|
| Price | $24.99 | $27.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $28.00 | ★ $45.00 |
| AVG Volume (30 Days) | 61.6K | ★ 93.1K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $2.54 | N/A |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.82 | $17.06 |
| 52 Week High | $29.59 | $30.56 |
| Indicator | IGIC | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 53.04 |
| Support Level | $24.51 | $25.00 |
| Resistance Level | $25.97 | $29.90 |
| Average True Range (ATR) | 0.59 | 1.67 |
| MACD | -0.12 | -0.14 |
| Stochastic Oscillator | 6.53 | 49.22 |
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.